This site is intended for health professionals only

New drug to battle MRSA superbugs


The fight against hospital superbugs has been stepped up with the study of the oral antibiotic EDP-322, a first-in-class MRSA-active bicyclolide.

The novel macrolide-related drug has a distinct resistance profile, and the clinical development program will include the treatment of hospital and community-acquired gram-positive infections.

Enanta Pharmaceuticals said that EDP-322 has demonstrated strong in-vitro activity against hospital-acquired MRSA strains resistant to Vancomycin, Zyvox (linezolid), and Cubican (daptomycin).

Robert Moellering, a professor of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center said: “Macrolides have been commonly prescribed to treat community infections for decades due to their convenient oral dosing and favourable safety profile.

“Now, with the discovery of a new generation of macrolides having high potency against hospital-acquired pathogens and a distinct resistance profile relative to other hospital antibiotics, there is a tremendous new opportunity to explore their use within not only the community, but the hospital setting as well.”

Enanta spokesman Yat Sun Or said, “In our in-vitro studies, EDP-322 demonstrated good potency against both hospital and community acquired MRSA, even against highly drug-resistant MRSA strains. The potency of EDP-322 against gram-positive pathogens has the potential to uniquely position EDP-322 among marketed MRSA drugs.”

Copyright PA Business 2008

Enanta Pharmaceuticals

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine